ABCL-185 Mosunetuzumab wWth Polatuzumab Vedotin: Subgroup Analyses in Patients (pts) With Primary Refractory or Early Relapsed Large B-Cell Lymphoma (LBCL)

Sarit Assouline,Lihua Elizabeth Budde,Sneha Makadia,Seema Naik,Michael C Wei,Song Pham,Nilanjan Ghosh,Catherine S Diefenbach,Iris To,Dipenkumar Modi,Adam J Olszewski,Connie Lee Batlevi,Manali Kamdar,Kathleen Anne Dorritie,Stephen Douglas Smith,Amitkumar Mehta,Hao Wu,Izidore S Lossos,Julio C Chavez

doi:10.1016/s2152-2650(24)01494-0

ABCL-185 Mosunetuzumab wWth Polatuzumab Vedotin: Subgroup Analyses in Patients (pts) With Primary Refractory or Early Relapsed Large B-Cell Lymphoma (LBCL)

Sarit Assouline, Lihua Elizabeth Budde + Show 17 more

https://doi.org/10.1016/s2152-2650(24)01494-0

Copy DOI

Export

Save

Cite

Journal: Clinical Lymphoma Myeloma and Leukemia

Publication Date: Sep 1, 2024

#Large B-Cell Lymphoma #Relapsed B-Cell Lymphoma #Refractory B-Cell Lymphoma #Subgroup Analyses #Relapsed B-cell #Early B-Cell #Refractory B-Cell #Relapsed Lymphoma #Refractory Lymphoma #Relapsed Large B-cell Lymphoma

Abstract
Full-Text
Similar Papers

Abstract

Listen

ABCL-185 Mosunetuzumab wWth Polatuzumab Vedotin: Subgroup Analyses in Patients (pts) With Primary Refractory or Early Relapsed Large B-Cell Lymphoma (LBCL)

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Clinical Lymphoma Myeloma and Leukemia

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

ABCL-185 Mosunetuzumab wWth Polatuzumab Vedotin: Subgroup Analyses in Patients (pts) With Primary Refractory or Early Relapsed Large B-Cell Lymphoma (LBCL)